Journal: Scientific Reports
Article Title: Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses
doi: 10.1038/s41598-025-93187-y
Figure Lengend Snippet: BATF in relation to prognosis and sorafenib response in MCHH cohort. ( A ) Boxplot shows the distribution of BATF expression between resistant and sensitive samples. ( B , C ) IHC images and BATF-score based on IHC images showing the distribution of BATF expression between sorafenib resistant and sensitive samples (Red arrows: BATF + immune cells; black arrows: BATF- immune cells). ( D ) Paired plot shows the distribution of BATF expression between HCC and paracancer samples. ( E , F ) IHC images and BATF-score based on IHC images shows the distribution of BATF expression between HCC and paracancer samples (Black arrows: immune cells). ( G ) Kaplan-Meier curves of OS with high- and low-BATF expression groups. ( H ) Time-dependent ROC curve of BATF expression analysis for predicting OS at 1-, 2-, and 3-years. ( I ). Univariate and multivariate Cox regression analysis of BATF expression in HCC samples. ( J ) Kaplan-Meier curves of OS with high- and low-BATF score groups. ( K ) Time-dependent ROC curve of BATF-score analysis for predicting OS at 1-, 2-, and 3-years. ( M ) Univariate and multivariate Cox regression analysis of BATF-score expression in HCC samples. MCHH: Mengchao Hepatobiliary Hospital; IHC: Immunohistochemistry; HCC: Hepatocellular carcinoma; OS: Overall survival; ROC: Receiver operating characteristic; *: P < 0.05; **: P < 0.01.
Article Snippet: IHC staining were performed using the antibodies against BATF (1:15000, CSB-PA619074LA01HU, CUSABIO) as described previously.
Techniques: Expressing, Immunohistochemistry